Efficacy and Safety of Insulin Aspart Versus Glibenclamide in Type 2 Diabetes

Inclusion Criteria: * Type 2 diabetes * Diet therapy for at least 12 weeks, or diet therapy and oral hypoglycaemic agent(s) other than SU agents for at least 12 weeks * No previous treatment with insulin and/or SU agents * HbA1c between 7.5% and 10.0% * Body Mass Index (BMI) below 30.0 kg/m2 Exclusion Criteria: * Proliferative retinopathy or maculopathy requiring acute treatment * Impaired hepatic function * Impaired renal function * Cardiac diseases * Uncontrolled hypertension * Known hypoglycaemia unawareness or recurrent major hypoglycaemia * Current treatment with systemic corticosteroids